Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

@article{Richeldi2011EfficacyOA,
  title={Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.},
  author={Luca Richeldi and Ulrich Costabel and Mois{\'e}s Selman and Dong Soon Kim and David M. Hansell and Andrew G. Nicholson and Kevin K. Brown and Kevin R. Flaherty and Paul W. Noble and Ganesh Raghu and Mich{\`e}le Brun and Abhya Gupta and Nolwenn Juhel and Matthias Klueglich and Roland M du Bois},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 12},
  pages={1079-87}
}
BACKGROUND Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as… CONTINUE READING
Highly Influential
This paper has highly influenced 22 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 30 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 236 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…